有关阿尔茨海默病的神经影像学应用和进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v7i2.13435
Abstract
阿尔茨海默病(Alzheimer's disease,AD)是以进行性认知域损害伴精神行为异常为临床特征的神经系统退行性疾病,目前缺乏有效治疗措施,给患者家庭和社会带来了沉重的负担,因此早期诊治非常重要。神经影像技术通过多模态整合策略——包括结构成像、功能连接分析、分子示踪及代谢评估等,为AD及临床前阶段的发病机制、临床诊断和预后等提供必须的客观量化依据。本研究整合AD及临床前阶段神经影像领域重要研究进展,以此为基础并从多个角度探索患者脑结构变化及病理生理机制,为AD的诊治提供相应的理论学基础。
Keywords
阿尔茨海默病;轻度认知障碍;神经影像学;磁共振成像;功能磁共振成像;正电子发射计算机断层显像
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Bloom G S.Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis[J].JAMA Neurol,2014,71(4):505-8.
[2] Mckhann G M,Knopman D S,Chertkow H,et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workg roups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement,2011,7(3):263-9.
[3] Jack C R,Jr.,Andrews J S,Beach T G,et al.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup[J]. Alzheimers Dement,2024,20(8):5143-5169.
[4] Yoon H J, Kim B S, Jeong J H, et al. Asymmetric Amyloid Deposition as an Early Sign of Progression in Mild Cognitive Impairment Due to Alzheimer Disease[J].Clin Nucl Med,2021,46(7):527-531.
[5] Kitajima K, Abe K, Takeda M, et al. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease[J].Medicine (Baltimore), 2021,100(3):e23969.
[6] Kjeldsen P L, Parbo P, Hansen K V, et al. Asymmetric amyloid deposition in preclinical Alzheimer's disease: A PET study[J].Aging Brain,2022,2:100048.
[7] Braak H,Braak E.Neuropathological stageing of Alzheim er-related changes[J]. Acta Neuropathol,1991,82(4):239-59.
[8] Soleimani-Meigooni D N, Iaccarino L, La Joie R, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases[J].Brain,2020,143 (11):3477-3494.
[9] Wolters E E,Dodich A,Boccardi M, et al. Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework[J]. Eur J Nucl Med Mol Imaging,2021,48(7):2097-2109.
[10] Sala A,Caprioglio C,Santangelo R,et al.Brain metabol ic signatures across the Alzheimer's disease spectrum[J]. Eur J Nucl Med Mol Imaging,2020,47(2):256-269.
[11] Santangelo R,Masserini F,Agosta F,et al.CSF p-tau/ Aβ(42) ratio and brain FDG-PET may reliably detect MCI "imminent" converters to AD[J]. Eur J Nucl Med Mol Imaging,2020,47(13):3152-3164.
[12] Ewers M, Brendel M, Rizk-Jackson A, et al. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects[J]. Neuroim age Clin,2014,4:45-52.
[2] Mckhann G M,Knopman D S,Chertkow H,et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workg roups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement,2011,7(3):263-9.
[3] Jack C R,Jr.,Andrews J S,Beach T G,et al.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup[J]. Alzheimers Dement,2024,20(8):5143-5169.
[4] Yoon H J, Kim B S, Jeong J H, et al. Asymmetric Amyloid Deposition as an Early Sign of Progression in Mild Cognitive Impairment Due to Alzheimer Disease[J].Clin Nucl Med,2021,46(7):527-531.
[5] Kitajima K, Abe K, Takeda M, et al. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease[J].Medicine (Baltimore), 2021,100(3):e23969.
[6] Kjeldsen P L, Parbo P, Hansen K V, et al. Asymmetric amyloid deposition in preclinical Alzheimer's disease: A PET study[J].Aging Brain,2022,2:100048.
[7] Braak H,Braak E.Neuropathological stageing of Alzheim er-related changes[J]. Acta Neuropathol,1991,82(4):239-59.
[8] Soleimani-Meigooni D N, Iaccarino L, La Joie R, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases[J].Brain,2020,143 (11):3477-3494.
[9] Wolters E E,Dodich A,Boccardi M, et al. Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework[J]. Eur J Nucl Med Mol Imaging,2021,48(7):2097-2109.
[10] Sala A,Caprioglio C,Santangelo R,et al.Brain metabol ic signatures across the Alzheimer's disease spectrum[J]. Eur J Nucl Med Mol Imaging,2020,47(2):256-269.
[11] Santangelo R,Masserini F,Agosta F,et al.CSF p-tau/ Aβ(42) ratio and brain FDG-PET may reliably detect MCI "imminent" converters to AD[J]. Eur J Nucl Med Mol Imaging,2020,47(13):3152-3164.
[12] Ewers M, Brendel M, Rizk-Jackson A, et al. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects[J]. Neuroim age Clin,2014,4:45-52.
Copyright © 2025 骆文仪, 赵翠

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License